生物標記在發炎性腸道疾病之應用

10.6666/ClinMed.201809_82(3).0101

蔡易展；林春吉

發炎性腸道疾病 ； 潰瘍性大腸炎 ； 克隆氏症 ； 生物標記

臨床醫學月刊

82卷3期（2018 / 09 / 28）

554 - 557

繁體中文

發炎性腸道疾病是腸胃系統的慢性發炎疾患。因為來發炎性腸道疾病需要更精準、非侵入及客觀的評估發炎狀況，生物標記在近期有非常多的發展。本文就診斷、評估疾病嚴重度、治療效果、評估復發的各個面向來介紹目前臨床上用來評估腸道發炎狀態的各種生物標記。

1. Costa, F,Mumolo, MG,Ceccarelli, L(2005).Calprotectin is a stronger predictive marker of relapse in ulcerative colitis thanin Crohn's disease.Gut,54,364-368.
2. D'Haens, G,Ferrante, M,Vermeire, S(2012).Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.Inflamm Bowel Dis,18,2218-2224.
3. Garcia-Sanchez, V,Iglesias-Flores, E,Gonzalez, R(2010).Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?.J Crohns Colitis,4,144-152.
4. Kaiser, T,Langhorst, J,Wittkowski, H(2007).Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.Gut,56,1706-1713.
5. Lasson, A,Simren, M,Stotzer, PO(2013).Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis.Inflamm Bowel Dis,19,576-581.
6. Menees, SB,Powell, C,Kurlander, J(2015).A meta-analysis of the utility of C-reactive protein, erythrocytesedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.Am J Gastroenterol,110,444-454.
7. Molodecky, NA,Soon, IS,Rabi, DM(2012).Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.Gastroenterology,142,46-54.
8. Pepys, MB,Druguet, M,Klass, HJ(1977).Immunological studies in inflammatory bowel disease.Ciba Found Symp,46,283-304.
9. Regueiro, M,Kip, KE,Schraut, W(2011).Crohns disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection.Inflamm Bowel Dis,17,118-126.
10. Sands, BE(2015).Biomarkers of Inflammation in Inflammatory Bowel Disease.Gastroenterology,149,1275-1285.
11. Schoepfer, AM,Beglinger, C,Straumann, A(2013).Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.Inflamm Bowel Dis,19,332-341.
12. Sipponen, T,Savilahti, E,Kolho, KL(2008).Crohns disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.Inflamm Bowel Dis,14,40-46.
13. Solem, CA,Loftus, EV., Jr.,Tremaine, WJ(2005).Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatorybowel disease.Inflamm Bowel Dis,11,707-712.
14. van Rheenen, PF,Van de Vijver, E,Fidler, V(2010).Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.BMJ,341,c3369.
15. Vermeire, S,Van Assche, G,Rutgeerts, P(2006).Laboratory markers in IBD: useful, magic, or unnecessary toys?.Gut,55,426-431.
16. Wright, EK,Kamm, MA,De Cruz, P(2015).Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.Gastroenterology,148,938-947.

1. 許翠純(2022)。運用個案管理模式照顧一位克隆氏症病人之護理經驗。彰化護理，29(3)，127-141。